Cargando…

Seroprevalence of SARS-CoV-2 in Niger State: Pilot Cross-Sectional Study

BACKGROUND: The COVID-19 pandemic caused by SARS-CoV-2 is causing ongoing human and socioeconomic losses. OBJECTIVE: To know how far the virus has spread in Niger State, Nigeria, a pilot study was carried out to determine the SARS-CoV-2 seroprevalence, patterns, dynamics, and risk factors in the sta...

Descripción completa

Detalles Bibliográficos
Autores principales: Majiya, Hussaini, Aliyu-Paiko, Mohammed, Balogu, Vincent Tochukwu, Musa, Dickson Achimugu, Salihu, Ibrahim Maikudi, Kawu, Abdullahi Abubakar, Bashir, Ishaku Yakubu, Sani, Aishat Rabiu, Baba, John, Muhammad, Amina Tako, Jibril, Fatimah Ladidi, Bala, Ezekiel, Obaje, Nuhu George, Aliyu, Yahaya Badeggi, Muhammad, Ramatu Gogo, Mohammed, Hadiza, Gimba, Usman Naji, Uthman, Abduljelili, Liman, Hadiza Muhammad, Alhaji, Sule Alfa, James, Joseph Kolo, Makusidi, Muhammad Muhammad, Isah, Mohammed Danasabe, Abdullahi, Ibrahim, Ndagi, Umar, Waziri, Bala, Bisallah, Chindo Ibrahim, Dadi-Mamud, Naomi John, Ibrahim, Kolo, Adamu, Abu Kasim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JMIR Publications Inc 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10595504/
https://www.ncbi.nlm.nih.gov/pubmed/37855218
http://dx.doi.org/10.2196/29587
_version_ 1785124883144900608
author Majiya, Hussaini
Aliyu-Paiko, Mohammed
Balogu, Vincent Tochukwu
Musa, Dickson Achimugu
Salihu, Ibrahim Maikudi
Kawu, Abdullahi Abubakar
Bashir, Ishaku Yakubu
Sani, Aishat Rabiu
Baba, John
Muhammad, Amina Tako
Jibril, Fatimah Ladidi
Bala, Ezekiel
Obaje, Nuhu George
Aliyu, Yahaya Badeggi
Muhammad, Ramatu Gogo
Mohammed, Hadiza
Gimba, Usman Naji
Uthman, Abduljelili
Liman, Hadiza Muhammad
Alhaji, Sule Alfa
James, Joseph Kolo
Makusidi, Muhammad Muhammad
Isah, Mohammed Danasabe
Abdullahi, Ibrahim
Ndagi, Umar
Waziri, Bala
Bisallah, Chindo Ibrahim
Dadi-Mamud, Naomi John
Ibrahim, Kolo
Adamu, Abu Kasim
author_facet Majiya, Hussaini
Aliyu-Paiko, Mohammed
Balogu, Vincent Tochukwu
Musa, Dickson Achimugu
Salihu, Ibrahim Maikudi
Kawu, Abdullahi Abubakar
Bashir, Ishaku Yakubu
Sani, Aishat Rabiu
Baba, John
Muhammad, Amina Tako
Jibril, Fatimah Ladidi
Bala, Ezekiel
Obaje, Nuhu George
Aliyu, Yahaya Badeggi
Muhammad, Ramatu Gogo
Mohammed, Hadiza
Gimba, Usman Naji
Uthman, Abduljelili
Liman, Hadiza Muhammad
Alhaji, Sule Alfa
James, Joseph Kolo
Makusidi, Muhammad Muhammad
Isah, Mohammed Danasabe
Abdullahi, Ibrahim
Ndagi, Umar
Waziri, Bala
Bisallah, Chindo Ibrahim
Dadi-Mamud, Naomi John
Ibrahim, Kolo
Adamu, Abu Kasim
author_sort Majiya, Hussaini
collection PubMed
description BACKGROUND: The COVID-19 pandemic caused by SARS-CoV-2 is causing ongoing human and socioeconomic losses. OBJECTIVE: To know how far the virus has spread in Niger State, Nigeria, a pilot study was carried out to determine the SARS-CoV-2 seroprevalence, patterns, dynamics, and risk factors in the state. METHODS: A cross-sectional study design and clustered, stratified random sampling strategy were used to select 185 test participants across the state. SARS-CoV-2 IgG and IgM rapid test kits (colloidal gold immunochromatography lateral flow system) were used to determine the presence or absence of antibodies to the virus in the blood of sampled participants across Niger State from June 26 to 30, 2020. The test kits were validated using the blood samples of some of the Nigeria Center for Disease Control–confirmed positive and negative COVID-19 cases in the state. SARS-CoV-2 IgG and IgM test results were entered into the Epi Info questionnaire administered simultaneously with each test. Epi Info was then used to calculate the arithmetic mean and percentage, odds ratio, χ(2) statistic, and regression at a 95% CI of the data generated. RESULTS: The seroprevalence of SARS-CoV-2 in Niger State was found to be 25.4% (47/185) and 2.2% (4/185) for the positive IgG and IgM results, respectively. Seroprevalence among age groups, genders, and occupations varied widely. The COVID-19 asymptomatic rate in the state was found to be 46.8% (22/47). The risk analyses showed that the chances of infection are almost the same for both urban and rural dwellers in the state. However, health care workers, those who experienced flulike symptoms, and those who had contact with a person who traveled out of Nigeria in the last 6 months (February to June 2020) were at double the risk of being infected with the virus. More than half (101/185, 54.6%) of the participants in this study did not practice social distancing at any time since the pandemic started. Participants’ knowledge, attitudes, and practices regarding COVID-19 are also discussed. CONCLUSIONS: The observed Niger State SARS-CoV-2 seroprevalence and infection patterns meansuggest that the virus has widely spread, far more SARS-CoV-2 infections have occurred than the reported cases, and there is a high asymptomatic COVID-19 rate across the state.
format Online
Article
Text
id pubmed-10595504
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher JMIR Publications Inc
record_format MEDLINE/PubMed
spelling pubmed-105955042023-10-25 Seroprevalence of SARS-CoV-2 in Niger State: Pilot Cross-Sectional Study Majiya, Hussaini Aliyu-Paiko, Mohammed Balogu, Vincent Tochukwu Musa, Dickson Achimugu Salihu, Ibrahim Maikudi Kawu, Abdullahi Abubakar Bashir, Ishaku Yakubu Sani, Aishat Rabiu Baba, John Muhammad, Amina Tako Jibril, Fatimah Ladidi Bala, Ezekiel Obaje, Nuhu George Aliyu, Yahaya Badeggi Muhammad, Ramatu Gogo Mohammed, Hadiza Gimba, Usman Naji Uthman, Abduljelili Liman, Hadiza Muhammad Alhaji, Sule Alfa James, Joseph Kolo Makusidi, Muhammad Muhammad Isah, Mohammed Danasabe Abdullahi, Ibrahim Ndagi, Umar Waziri, Bala Bisallah, Chindo Ibrahim Dadi-Mamud, Naomi John Ibrahim, Kolo Adamu, Abu Kasim JMIRx Med Original Paper BACKGROUND: The COVID-19 pandemic caused by SARS-CoV-2 is causing ongoing human and socioeconomic losses. OBJECTIVE: To know how far the virus has spread in Niger State, Nigeria, a pilot study was carried out to determine the SARS-CoV-2 seroprevalence, patterns, dynamics, and risk factors in the state. METHODS: A cross-sectional study design and clustered, stratified random sampling strategy were used to select 185 test participants across the state. SARS-CoV-2 IgG and IgM rapid test kits (colloidal gold immunochromatography lateral flow system) were used to determine the presence or absence of antibodies to the virus in the blood of sampled participants across Niger State from June 26 to 30, 2020. The test kits were validated using the blood samples of some of the Nigeria Center for Disease Control–confirmed positive and negative COVID-19 cases in the state. SARS-CoV-2 IgG and IgM test results were entered into the Epi Info questionnaire administered simultaneously with each test. Epi Info was then used to calculate the arithmetic mean and percentage, odds ratio, χ(2) statistic, and regression at a 95% CI of the data generated. RESULTS: The seroprevalence of SARS-CoV-2 in Niger State was found to be 25.4% (47/185) and 2.2% (4/185) for the positive IgG and IgM results, respectively. Seroprevalence among age groups, genders, and occupations varied widely. The COVID-19 asymptomatic rate in the state was found to be 46.8% (22/47). The risk analyses showed that the chances of infection are almost the same for both urban and rural dwellers in the state. However, health care workers, those who experienced flulike symptoms, and those who had contact with a person who traveled out of Nigeria in the last 6 months (February to June 2020) were at double the risk of being infected with the virus. More than half (101/185, 54.6%) of the participants in this study did not practice social distancing at any time since the pandemic started. Participants’ knowledge, attitudes, and practices regarding COVID-19 are also discussed. CONCLUSIONS: The observed Niger State SARS-CoV-2 seroprevalence and infection patterns meansuggest that the virus has widely spread, far more SARS-CoV-2 infections have occurred than the reported cases, and there is a high asymptomatic COVID-19 rate across the state. JMIR Publications Inc 2023-10-17 /pmc/articles/PMC10595504/ /pubmed/37855218 http://dx.doi.org/10.2196/29587 Text en © Hussaini Majiya, Mohammed Aliyu-Paiko, Vincent Tochukwu Balogu, Dickson Achimugu Musa, Ibrahim Maikudi Salihu, Abdullahi Abubakar Kawu, Ishaku Yakubu Bashir, Aishat Rabiu Sani, John Baba, Amina Tako Muhammad, Fatimah Ladidi Jibril, Ezekiel Bala, Nuhu George Obaje, Yahaya Badeggi Aliyu, Ramatu Gogo Muhammad, Hadiza Mohammed, Usman Naji Gimba, Abduljelili Uthman, Hadiza Muhammad Liman, Sule Alfa Alhaji, Joseph Kolo James, Muhammad Muhammad Makusidi, Mohammed Danasabe Isah, Ibrahim Abdullahi, Umar Ndagi, Bala Waziri, Chindo Ibrahim Bisallah, Naomi John Dadi-Mamud, Kolo Ibrahim, Abu Kasim Adamu. Originally published in JMIRx Med (https://med.jmirx.org), 17.10.2023. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIRx Med, is properly cited. The complete bibliographic information, a link to the original publication on https://med.jmirx.org/, as well as this copyright and license information must be included.
spellingShingle Original Paper
Majiya, Hussaini
Aliyu-Paiko, Mohammed
Balogu, Vincent Tochukwu
Musa, Dickson Achimugu
Salihu, Ibrahim Maikudi
Kawu, Abdullahi Abubakar
Bashir, Ishaku Yakubu
Sani, Aishat Rabiu
Baba, John
Muhammad, Amina Tako
Jibril, Fatimah Ladidi
Bala, Ezekiel
Obaje, Nuhu George
Aliyu, Yahaya Badeggi
Muhammad, Ramatu Gogo
Mohammed, Hadiza
Gimba, Usman Naji
Uthman, Abduljelili
Liman, Hadiza Muhammad
Alhaji, Sule Alfa
James, Joseph Kolo
Makusidi, Muhammad Muhammad
Isah, Mohammed Danasabe
Abdullahi, Ibrahim
Ndagi, Umar
Waziri, Bala
Bisallah, Chindo Ibrahim
Dadi-Mamud, Naomi John
Ibrahim, Kolo
Adamu, Abu Kasim
Seroprevalence of SARS-CoV-2 in Niger State: Pilot Cross-Sectional Study
title Seroprevalence of SARS-CoV-2 in Niger State: Pilot Cross-Sectional Study
title_full Seroprevalence of SARS-CoV-2 in Niger State: Pilot Cross-Sectional Study
title_fullStr Seroprevalence of SARS-CoV-2 in Niger State: Pilot Cross-Sectional Study
title_full_unstemmed Seroprevalence of SARS-CoV-2 in Niger State: Pilot Cross-Sectional Study
title_short Seroprevalence of SARS-CoV-2 in Niger State: Pilot Cross-Sectional Study
title_sort seroprevalence of sars-cov-2 in niger state: pilot cross-sectional study
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10595504/
https://www.ncbi.nlm.nih.gov/pubmed/37855218
http://dx.doi.org/10.2196/29587
work_keys_str_mv AT majiyahussaini seroprevalenceofsarscov2innigerstatepilotcrosssectionalstudy
AT aliyupaikomohammed seroprevalenceofsarscov2innigerstatepilotcrosssectionalstudy
AT baloguvincenttochukwu seroprevalenceofsarscov2innigerstatepilotcrosssectionalstudy
AT musadicksonachimugu seroprevalenceofsarscov2innigerstatepilotcrosssectionalstudy
AT salihuibrahimmaikudi seroprevalenceofsarscov2innigerstatepilotcrosssectionalstudy
AT kawuabdullahiabubakar seroprevalenceofsarscov2innigerstatepilotcrosssectionalstudy
AT bashirishakuyakubu seroprevalenceofsarscov2innigerstatepilotcrosssectionalstudy
AT saniaishatrabiu seroprevalenceofsarscov2innigerstatepilotcrosssectionalstudy
AT babajohn seroprevalenceofsarscov2innigerstatepilotcrosssectionalstudy
AT muhammadaminatako seroprevalenceofsarscov2innigerstatepilotcrosssectionalstudy
AT jibrilfatimahladidi seroprevalenceofsarscov2innigerstatepilotcrosssectionalstudy
AT balaezekiel seroprevalenceofsarscov2innigerstatepilotcrosssectionalstudy
AT obajenuhugeorge seroprevalenceofsarscov2innigerstatepilotcrosssectionalstudy
AT aliyuyahayabadeggi seroprevalenceofsarscov2innigerstatepilotcrosssectionalstudy
AT muhammadramatugogo seroprevalenceofsarscov2innigerstatepilotcrosssectionalstudy
AT mohammedhadiza seroprevalenceofsarscov2innigerstatepilotcrosssectionalstudy
AT gimbausmannaji seroprevalenceofsarscov2innigerstatepilotcrosssectionalstudy
AT uthmanabduljelili seroprevalenceofsarscov2innigerstatepilotcrosssectionalstudy
AT limanhadizamuhammad seroprevalenceofsarscov2innigerstatepilotcrosssectionalstudy
AT alhajisulealfa seroprevalenceofsarscov2innigerstatepilotcrosssectionalstudy
AT jamesjosephkolo seroprevalenceofsarscov2innigerstatepilotcrosssectionalstudy
AT makusidimuhammadmuhammad seroprevalenceofsarscov2innigerstatepilotcrosssectionalstudy
AT isahmohammeddanasabe seroprevalenceofsarscov2innigerstatepilotcrosssectionalstudy
AT abdullahiibrahim seroprevalenceofsarscov2innigerstatepilotcrosssectionalstudy
AT ndagiumar seroprevalenceofsarscov2innigerstatepilotcrosssectionalstudy
AT waziribala seroprevalenceofsarscov2innigerstatepilotcrosssectionalstudy
AT bisallahchindoibrahim seroprevalenceofsarscov2innigerstatepilotcrosssectionalstudy
AT dadimamudnaomijohn seroprevalenceofsarscov2innigerstatepilotcrosssectionalstudy
AT ibrahimkolo seroprevalenceofsarscov2innigerstatepilotcrosssectionalstudy
AT adamuabukasim seroprevalenceofsarscov2innigerstatepilotcrosssectionalstudy